Change in hemostatic markers after recombinant tissue-type plasminogen activator is not associated with the chance of recanalization.
OBJECTIVE
We evaluated the association between recombinant tissue-type plasminogen activator recanalization and change in hemostatic markers.


METHODS
We studied 40 patients. Recanalization was measured with transcranial Doppler. We evaluated the change in markers of coagulation (fibrinogen) and fibrinolysis (thrombin activatable fibrinolysis inhibitor and alpha(2)-antiplasmin) in patients with ischemic stroke treated with recombinant tissue-type plasminogen activator. Samples were obtained before and 90 minutes after recombinant tissue-type plasminogen activator infusion.


RESULTS
The analyses (2-way analysis of variance) showed that the change in the value of each marker did not depend on the vascular patency status.


CONCLUSIONS
From a practical point of view, the measurement of these hemostatic markers is probably not useful for predicting recanalization.
Joan
J
Martí-Fàbregas
Montserrat
M
Borrell
Dolores
D
Cocho
Sergi
S
Martínez-Ramírez
Mercè
M
Martínez-Corral
Jordi
J
Fontcuberta
Josep-Lluis
JL
Martí-Vilalta
D000368:Aged; D015415:Biomarkers / Q000097:blood; D001921:Brain / Q000098:blood supply; D025901:Carboxypeptidase B2 / Q000097:blood*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism*; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D020521:Stroke / Q000097:blood* / Q000188:drug therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000494:pharmacology* / Q000627:therapeutic use; D017585:Ultrasonography, Doppler, Transcranial; D000979:alpha-2-Antiplasmin / Q000378:metabolism*
D015415:Biomarkers; D005343:Fibrinolytic Agents; D000979:alpha-2-Antiplasmin; D005340:Fibrinogen; D025901:Carboxypeptidase B2; D010959:Tissue Plasminogen Activator